Q-omics provides the consensus-scored FLAD1 profile across patient tissues and cancer cell-line models. FLAD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FLAD1 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, FLAD1 RNA expression shows 20,255 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where FLAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FLAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FLAD1 survival associations across molecular data types. FLAD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FLAD1 RNA expression–survival associations across cancer types. High FLAD1 expression shows unfavorable associations in KIRC, ACC, UVM, LIHC, SKCM and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FLAD1 RNA expression.
This table summarizes FLAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FLAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FLAD1 shows higher tumor expression in BLCA, HNSC, COAD, KIRC, LIHC and LUAD. The BLCA box plot shows higher FLAD1 RNA expression in tumor versus normal tissue (log2 FC = +1.369, t-test p < 0.001).
This table shows molecular features associated with FLAD1 in patient tissues and cancer cell lines. In patient samples, FLAD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FLAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
